Ultrasensitive Digital Immunoassay for PSA by Single Molecule Array (Simoa™) Technology in Prostatectomy Patients

Measurement of prostate‐specific antigen (PSA) following radical prostatectomy (RP) has become standard practice for monitoring prostate cancer recurrence. Plasma PSA levels following surgery are typically undetectable by most assay methods, and it is generally agreed that undetectable postsurgical PSA over time indicates a good prognosis. Quanterix™ has developed an ultra‐sensitive platform that can measure individual proteins at concentrations 1000 times lower than current immunoassays available today. The Single Molecule Array (Simoa™) technology at the heart of this platform enables the detection and quantification of biomarkers previously difficult or impossible to measure.